Search Result

Results for "

2C19

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Apoptosis (3) Autophagy (14) Bacterial (12) Bcl-2 Family (1) Calcium Channel (1) CaMK (1) Cannabinoid Receptor (2) Caspase (1) Cholinesterase (ChE) (1) Cytochrome P450 (63) DNA/RNA Synthesis (1) Drug Metabolite (7) Endogenous Metabolite (1) FGFR (1) Fluorescent Dye (1) Fungal (2) Glucocorticoid Receptor (2) HBV (1) HCV Protease (2) Histamine Receptor (7) HIV (2) IDE (1) Influenza Virus (1) Insecticide (1) Isotope-Labeled Compounds (10) JAK (1) MDM-2/p53 (1) MEK (1) Mixed Lineage Kinase (1) NAMPT (1) Notch (1) P2Y Receptor (3) Parasite (4) Phospholipase (7) PPAR (10) Proteolytic Enzyme (1) Proton Pump (9) Pyruvate Kinase (1) Reverse Transcriptase (1) Small Interfering RNA (siRNA) (1) Virus Protease (2) β-catenin (1) γ-secretase (1)
By Research Areas:	Cancer (31) Cardiovascular Disease (18) Endocrinology (4) Infection (27) Inflammation/Immunology (5) Metabolic Disease (28) Neurological Disease (23)
Oligonucleotides:	Human Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0725S

Doxepin D3 Hydrochloride	Histamine Receptor Cytochrome P450	Neurological Disease
Doxepin-d₃ (hydrochloride) is a deuterium labeled Doxepin Hydrochloride. Doxepin hydrochloride is an orally active tricyclic antidepressant. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2[1][2].

HY-B0258

Gemfibrozil 1 Publications Verification CI-719	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-148822

Nampt activator-2	NAMPT	Neurological Disease
Nampt activator-2 (compound 34) is a potent NAMPT activator, with EC₅₀ of 0.023 μM. Nampt activator-2 shows moderate activity against CYP2C9 (0.060 μM), 2D6 (0.41 μM) and 2C19 (0.59 μM) .

HY-B0258R

Gemfibrozil (Standard) 1 Publications Verification CI-719 (Standard)	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil (Standard) is the analytical standard of Gemfibrozil. This product is intended for research and analytical applications. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-117026

LKY-047	Cytochrome P450	Metabolic Disease Inflammation/Immunology
LKY-047, a Decursin derivative, is a potent and selective reversible competitive cytochrome P45022J2 (CYP2J2) inhibitor with an IC₅₀ of 1.7 μM. LKY-047 is inactive against other human P450s, such as CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, and 3A .

HY-113739

Desmethylcitalopram hydrochloride DCIT hydrochloride	Cytochrome P450	Neurological Disease
Desmethylcitalopram (DCIT) hydrochloride is the active metabolite of Citalopram (HY-121203). Desmethylcitalopram has antidepressant effects. Desmethylcitalopram also inhibits cytochrome P450-2D6, -2C19 with IC₅₀s of 39.5 and 53.5 μM .

HY-113739A

(S)-Desmethylcitalopram (S)-DCIT	Cytochrome P450	Neurological Disease
(S)-Desmethylcitalopram is the isomer of Desmethylcitalopram hydrochloride (HY-113739). Desmethylcitalopram (DCIT) hydrochloride is the active metabolite of Citalopram (HY-121203). Desmethylcitalopram has antidepressant effects. Desmethylcitalopram also inhibits cytochrome P450-2D6，-2C19 with IC₅₀s of 39.5 and 53.5 μM .

HY-113739S1

Desmethylcitalopram-d4 hydrochloride DCIT-d₄ hydrochloride	Cytochrome P450 Isotope-Labeled Compounds	Neurological Disease
Desmethylcitalopram-d₄ hydrochloride is deuterated labeled Desmethylcitalopram hydrochloride (HY-113739). Desmethylcitalopram (DCIT) hydrochloride is the active metabolite of Citalopram (HY-121203). Desmethylcitalopram has antidepressant effects. Desmethylcitalopram also inhibits cytochrome P450-2D6, -2C19 with IC₅₀s of 39.5 and 53.5 μM .

HY-B0258S

Gemfibrozil-d6 CI-719-d₆	PPAR Cytochrome P450	Cardiovascular Disease Metabolic Disease
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-B0258S1

Gemfibrozil-d6-1 CI-719-d₆-1	Cytochrome P450 PPAR Isotope-Labeled Compounds	Cardiovascular Disease Metabolic Disease Cancer
Gemfibrozil-d6-1 (CI-719-d6-1) is the deuterium labeled Gemfibrozil (HY-B0258). Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively .

HY-B0725

Doxepin Hydrochloride 4 Publications Verification	Histamine Receptor Cytochrome P450	Neurological Disease Cancer
Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 . Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant . . Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system . . Doxepin has also been proposed as a protective factor against oxidative stress . .

HY-151254

CYP2C19-IN-1	Cytochrome P450 Influenza Virus DNA/RNA Synthesis	Infection
CYP2C19-IN-1 (compound 20d) is a potent *CYP2C19* inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C19-IN-1 inhibits RNA-dependent RNA polymerase (RdRP) with a K_i value of 6.16 µM. CYP2C19-IN-1 can be used in study of anti-ZIKV .

HY-148907

CS640	CaMK MEK Mixed Lineage Kinase	Cancer
CS640 is a selective inhibitor of calmodulin-dependent kinases. CS640 inhibits CaMK1D, CaMK1B, CaMK1A, CaMK1G, PIP5K1C, MEK5, RIPK4 and MLK3 with IC₅₀ values of 0.08, 0.03, 0.001, 0.001, 11.2, 0.025, 5.69 and 2.75 μM, respectively. CS640 also shows inhibitory effects to CYP450 2C9 and CYP450 2C19 with IC₅₀ values of 6 and 10 μM, respectively .

HY-B0725R

Doxepin (Hydrochloride) (Standard)	Histamine Receptor Cytochrome P450	Neurological Disease Cancer
Doxepin (Hydrochloride) (Standard) is the analytical standard of Doxepin (Hydrochloride). This product is intended for research and analytical applications. Doxepin hydrochloride is an orally active tricyclic antidepressant agent. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2 . Doxepin inhibits reuptake of serotonin and norepinephrine as a tricyclic antidepressant . . Doxepin has therapeutic effects in atopic dermatitis，chronic urticarial，can improve cognitive processes， protect central nervous system . . Doxepin has also been proposed as a protective factor against oxidative stress . .

HY-E70479

Human CYP2C19,Low-Reductase	Cytochrome P450	Metabolic Disease
Human CYP2C19, Low-Reductase, a recombinant CYP2C19, is a member of the CYP enzyme family. CYP2C19 catalyzes metabolism of xenobiotics, including some proton pump inhibitors and antiepileptic drugs .

HY-E70462

Human CYP2C19,High-Reductase	Cytochrome P450	Metabolic Disease
Human CYP2C19, High-Reductase, a recombinant CYP2C19, is a member of the CYP enzyme family. CYP2C19 catalyzes metabolism of xenobiotics, including some proton pump inhibitors and antiepileptic drugs .

HY-E70505

Human CYP2C19,Low-Reductase+b5	Cytochrome P450	Metabolic Disease
Human CYP2C19, Low-Reductase+b5, a recombinant CYP2C19, is a member of the CYP enzyme family. CYP2C19 catalyzes metabolism of xenobiotics, including some proton pump inhibitors and antiepileptic drugs .

HY-E70506

Human CYP2C19,High-Reductase+b5	Cytochrome P450	Metabolic Disease
Human CYP2C19, High-Reductase+b5, a recombinant CYP2C19, is a member of the CYP enzyme family. CYP2C19 catalyzes metabolism of xenobiotics, including some proton pump inhibitors and antiepileptic drugs .

HY-151253

CYP2C1/CYP2C19-IN-2	Cytochrome P450 Virus Protease	Infection
CYP2C1/CYP2C19-IN-2 (compound 21d) is a potent *CYP2C9/CYP2C19* inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C1/CYP2C19-IN-2 can be used in study of anti-ZIKV .

HY-151251

CYP2C9/CYP2C19-IN-1	Cytochrome P450 Virus Protease	Infection
CYP2C9/CYP2C19-IN-1 (compound 22d) is a potent *CYP2C9/CYP2C19* inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C9/CYP2C19-IN-1 can be used in study of anti-ZIKV .

HY-RS03458

CYP2C19 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CYP2C19 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP2C19 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CYP2C19 Human Pre-designed siRNA Set A CYP2C19 Human Pre-designed siRNA Set A

HY-B1184

Mephenytoin 1 Publications Verification	Cytochrome P450	Neurological Disease
Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate .

HY-W008772

4-Hydroxymephenytoin	Drug Metabolite	Others
4-Hydroxymephenytoin is a metabolism of an antiepileptic agent mephenytoin, which is used as a CYP2C19 substrate.

HY-B1184S1

Mephenytoin-d5	Cytochrome P450	Neurological Disease
Mephenytoin-d₅ is the deuterium labeled Mephenytoin. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate[1].

HY-B1184R

Mephenytoin (Standard)	Cytochrome P450	Neurological Disease
Mephenytoin (Standard) is the analytical standard of Mephenytoin. This product is intended for research and analytical applications. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate .

HY-B1184S2

Mephenytoin-d8	Cytochrome P450	Neurological Disease
Mephenytoin-d₈ is the deuterium labeled Mephenytoin[1]. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate[2].

HY-B2015

Carbosulfan	Cytochrome P450 Parasite	Infection
Carbosulfan inhibited relatively potently CYP3A4 and moderately CYP1A1/2 and CYP2C19 in pooled HLM (human livers).

HY-B1184S3

Mephenytoin-13C,d3	Isotope-Labeled Compounds Cytochrome P450	Neurological Disease
Mephenytoin-13C,d3 is a deuterated labeled Mephenytoin . Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate .

HY-W008772S

4-Hydroxymephenytoin-d3	Drug Metabolite	Others
4-Hydroxymephenytoin-d₃ is the deuterium labeled 4-Hydroxymephenytoin. 4-Hydroxymephenytoin is a metabolism of an antiepileptic agent mephenytoin, which is used as a CYP2C19 substrate[1][2].

HY-B1184A

(S)-Mephenytoin (+)-Mephenytoin	Cytochrome P450	Neurological Disease
(S)-Mephenytoin ((+)-Mephenytoin) is an anticonvulsive agent. (S)-Mephenytoin is a substrate of the cytochrome P450 (CYP) isoform CYP2C19. (S)-Mephenytoin can be used for the analysis of cytochrome P450 metabolism .

HY-118283

5-Hydroxylansoprazole 1 Publications Verification AG1908	Proton Pump	Metabolic Disease
5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole in plasma. Lansoprazole is metabolized by CYP2C19 forming 5-Hydroxylansoprazole. Lansoprazole is a gastric proton-pump inhibitor and is effective in the treatment of various peptic diseases .

HY-B0281A

Ranitidine hydrochloride 1 Publications Verification	Histamine Receptor Cytochrome P450 Bacterial	Infection Cardiovascular Disease Metabolic Disease Endocrinology Cancer
Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist with an IC₅₀ of 3.3 μM that inhibits gastric secretion. Ranitidine hydrochloride is a weak inhibitor of *CYP2C19* and CYP2C9 .

HY-W702646

Hydroxymethyl tolperisone hydrochloride	Drug Metabolite	Neurological Disease
Hydroxymethyl tolperisone hydrochloride is a metabolite of Tolperisone (HY-B1139A). Hydroxymethyl tolperisone hydrochloride is formed from tolperisone primarily by the cytochrome P450 (CYP) isoform CYP2D6 and to a lesser extent by CYP2C19 and CYP1A2.

HY-B0693

Ranitidine 1 Publications Verification	Histamine Receptor Bacterial Cytochrome P450	Infection Metabolic Disease Endocrinology Cancer
Ranitidine is a potent, selective and orally active histamine H2-receptor antagonist with an IC₅₀ of 3.3 μM that inhibits gastric secretion. Ranitidine is a weak inhibitor of *CYP2C19* and CYP2C9 .

HY-B2015S

Carbosulfan-d18	Cytochrome P450 Parasite	Infection
Carbosulfan-d₁₈ is the deuterium labeled Carbosulfan. Carbosulfan inhibited relatively potently CYP3A4 and moderately CYP1A1/2 and CYP2C19 in pooled HLM (human livers). Carbosulfan activation is predominantly catalyzed in humans by CYP3A4.

HY-103392

Stiripentol 3 Publications Verification BCX2600	Cytochrome P450	Neurological Disease
Stiripentol (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediatated by CYP3A4 (noncompetitively) and CYP2C19 (competitively) with K_i of 1.59±0.07 and 0.516±0.065 μM and IC₅₀ of 1.58 and 3.29 μM, respectively.

HY-124542

5-Hydroxydiclofenac	Drug Metabolite Apoptosis	Cancer
5-Hydroxydiclofenac is a major metabolite of Diclofenac (HY-15036). 5-Hydroxydiclofenac is formed by the cytochrome P450 (CYP) isoforms CYP3A4, CYP2C189, CYP2C19, and CYP2C8. 5-Hydroxydiclofenac shows apoptotic effects in hepatocytes .

HY-135111

4-Desmethoxy Omeprazole	Drug Metabolite	Infection Metabolic Disease Cancer
4-Desmethoxy Omeprazole is the active metabolite of Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .

HY-B1184AR

(S)-Mephenytoin (Standard)	Cytochrome P450	Neurological Disease
(S)-Mephenytoin (Standard) is the analytical standard of (S)-Mephenytoin. This product is intended for research and analytical applications. (S)-Mephenytoin ((+)-Mephenytoin) is an anticonvulsive agent. (S)-Mephenytoin is a substrate of the cytochrome P450 (CYP) isoform CYP2C19. (S)-Mephenytoin can be used for the analysis of cytochrome P450 metabolism .

HY-B0281AS

Ranitidine-d6 hydrochloride	Histamine Receptor Cytochrome P450 Bacterial	Infection Metabolic Disease Endocrinology
Ranitidine-d₆ (hydrochloride) is the deuterium labeled Ranitidine hydrochloride. Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist with an IC50 of 3.3 μM that inhibits gastric secretion. Ranitidine hydrochloride is a weak inhibitor of CYP2C19 and CYP2C9[1][2].

HY-B0113S

Omeprazole-d₃ 1 Publications Verification H 16868-d₃	Proton Pump Bacterial Autophagy	Infection Metabolic Disease Cancer
Omeprazole-d₃ is deuterium labeled Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].

HY-B0281AR

Ranitidine hydrochloride (Standard)	Histamine Receptor Cytochrome P450 Bacterial	Infection Metabolic Disease Endocrinology Cancer
Ranitidine (hydrochloride) (Standard) is the analytical standard of Ranitidine (hydrochloride). This product is intended for research and analytical applications. Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist with an IC₅₀ of 3.3 μM that inhibits gastric secretion. Ranitidine hydrochloride is a weak inhibitor of *CYP2C19* and CYP2C9 .

HY-N6023

Thermopsoside	Cytochrome P450	Others
Thermopsoside is a flavone derivative isolated from Aspalathus linearis. Thermopsoside exhibits inhibitory effects on CYP450 isozymes with IC₅₀ values of 6.0 μM, 9.5 μM, 12.0 μM, 32.0 μM, for CYP3A4, CYP2C19, CYP2D6 and CYP2C9, respectively .

HY-137258

(±)-N-3-Benzylnirvanol	Cytochrome P450	Metabolic Disease
(±)-N-3-Benzylnirvanol is a racemic mixture of (+)-N-3-Benzylnirvanol and (-)-N-3-Benzylnirvanol. (+)-N-3-Benzylnirvanol and (–)-N-3-Benzylnirvanol are potent and selective cytochrome P450 inhibitors with K_i values of 0.25 and 5.3 μM for *CYP2C19*, respectively .

HY-129923

(R)-Omeprazole sodium	Cytochrome P450	Neurological Disease
(R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19 .

HY-W157689

IDE-IN-2	Proteolytic Enzyme IDE	Infection Metabolic Disease Cancer
IDE-IN-3 (Compound 4) is an inhibitor for insulin-degrading enzyme. IDE-IN-3 is predicted to have CYP3A4, CYP2C19, hERG, NADP+, HIF1α and histidine kinase inhibitory activities, and has potential biological activity in anti-diabetic, anti-tumor, anti-bacterial aspects, according to the in silico prediction .

HY-103392S

Stiripentol-d9	Isotope-Labeled Compounds Cytochrome P450	Neurological Disease
Stiripentol-d₉ is the deuterium labeled Stiripentol. Stiripentol (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediatated by CYP3A4 (noncompetitively) and CYP2C19 (competitively) with Ki of 1.59±0.07 and 0.516±0.065 μM and IC50 of 1.58 and 3.29 μM, respectively[1][2].

HY-B0113A

Omeprazole sodium 5 Publications Verification H 16868 sodium	Proton Pump Autophagy Bacterial Phospholipase	Infection Metabolic Disease Cancer
Omeprazole sodium (H 16868 sodium), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole sodium shows competitive inhibition of *CYP2C19* activity with a K_i of 2 to 6 μM . Omeprazole sodium also inhibits growth of Gram-positive and Gram-negative bacteria . Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0113

Omeprazole 5 Publications Verification H 16868	Proton Pump Autophagy Bacterial Phospholipase	Infection Metabolic Disease Cancer
Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of *CYP2C19* activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-W008364

Olivetol	Cytochrome P450 Cannabinoid Receptor	Neurological Disease
Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2 . Olivetol also inhibits *CYP2C19* and CYP2D6 activity, with IC₅₀s of 15.3 μM, 7.21 μM and K_is of 2.71 μM, 2.87 μM, respectively .

Cat. No.	Product Name	Type

HY-116862

Dibenzylfluorescein

DBF

Fluorescent Dyes/Probes

Dibenzylfluorescein (DBF) is a fluorogenic probe (Fluoresecent dye) that acts as a substrate for specific cytochrome P450 (CYP) isoforms, including CYP3A4, CYP2C8, CYP2C9, CYP2C19, and aromatase (CYP19). Dibenzylfluorescein is typically used near its K_m value of 0.87-1.9 µM (Ex=485nm，Em=535nm). Dibenzylfluorescein is used to detect changes in CYP catalytic activity caused by drugs or disease .

HY-17356G

Fenofibrate (GMP)

Fluorescent Dye

Fenofibrate (GMP) is Fenofibrate (HY-17356) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

Cat. No.	Product Name	Type

HY-17356G

Fenofibrate (GMP)

Biochemical Assay Reagents

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W008772

4-Hydroxymephenytoin	Structural Classification Monophenols Classification of Application Fields Source classification Other Diseases Phenols Endogenous metabolite Disease Research Fields	Drug Metabolite
4-Hydroxymephenytoin is a metabolism of an antiepileptic agent mephenytoin, which is used as a CYP2C19 substrate.

HY-W008364

Olivetol	Structural Classification Microorganisms other families Source classification Phenols Polyphenols Plants	Cytochrome P450 Cannabinoid Receptor
Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2 . Olivetol also inhibits *CYP2C19* and CYP2D6 activity, with IC₅₀s of 15.3 μM, 7.21 μM and K_is of 2.71 μM, 2.87 μM, respectively .

HY-N6023

Thermopsoside	Flavonoids Classification of Application Fields Flavones Astragalus microcephalus Willd. Source classification Other Diseases Phenols Polyphenols Plants Compositae Disease Research Fields	Cytochrome P450
Thermopsoside is a flavone derivative isolated from Aspalathus linearis. Thermopsoside exhibits inhibitory effects on CYP450 isozymes with IC₅₀ values of 6.0 μM, 9.5 μM, 12.0 μM, 32.0 μM, for CYP3A4, CYP2C19, CYP2D6 and CYP2C9, respectively .

HY-W008364R

Olivetol (Standard)	Structural Classification Microorganisms other families Source classification Phenols Polyphenols Plants	Cytochrome P450 Cannabinoid Receptor
Olivetol (Standard) is the analytical standard of Olivetol. This product is intended for research and analytical applications. Olivetol is a naturally phenol found in lichens and produced by certain insects, acting as a competitive inhibitor of the cannabinoid receptors CB1 and CB2 . Olivetol also inhibits CYP2C19 and CYP2D6 activity, with IC50s of 15.3 μM, 7.21 μM and Kis of 2.71 μM, 2.87 μM, respectively .

HY-113371R

2-Methylcitric acid (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Source classification Disease markers Endocrine diseases Endogenous metabolite	Endogenous Metabolite
Omeprazole (sodium) (Standard) is the analytical standard of Omeprazole (sodium). This product is intended for research and analytical applications. Omeprazole sodium (H 16868 sodium), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole sodium shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM . Omeprazole sodium also inhibits growth of Gram-positive and Gram-negative bacteria . Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

Cat. No.	Product Name	Chemical Structure

HY-B0725S

Doxepin D3 Hydrochloride
Doxepin-d₃ (hydrochloride) is a deuterium labeled Doxepin Hydrochloride. Doxepin hydrochloride is an orally active tricyclic antidepressant. Doxepin hydrochloride is a potent and selective histamine receptor H1 antagonist. Doxepin hydrochloride is also a potent CYP450 inhibitor and significantly inhibits CYP450 2C19 and 1A2[1][2].

HY-B1184S1

Mephenytoin-d5
Mephenytoin-d₅ is the deuterium labeled Mephenytoin. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate[1].

HY-W008772S

4-Hydroxymephenytoin-d3
4-Hydroxymephenytoin-d₃ is the deuterium labeled 4-Hydroxymephenytoin. 4-Hydroxymephenytoin is a metabolism of an antiepileptic agent mephenytoin, which is used as a CYP2C19 substrate[1][2].

HY-B0281AS

Ranitidine-d6 hydrochloride
Ranitidine-d₆ (hydrochloride) is the deuterium labeled Ranitidine hydrochloride. Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist with an IC50 of 3.3 μM that inhibits gastric secretion. Ranitidine hydrochloride is a weak inhibitor of CYP2C19 and CYP2C9[1][2].

HY-113739S1

Desmethylcitalopram-d4 hydrochloride
Desmethylcitalopram-d₄ hydrochloride is deuterated labeled Desmethylcitalopram hydrochloride (HY-113739). Desmethylcitalopram (DCIT) hydrochloride is the active metabolite of Citalopram (HY-121203). Desmethylcitalopram has antidepressant effects. Desmethylcitalopram also inhibits cytochrome P450-2D6, -2C19 with IC₅₀s of 39.5 and 53.5 μM .

HY-B0258S

Gemfibrozil-d6
Gemfibrozil-d₆ is the deuterium labeled Gemfibrozil. Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with Ki values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively.

HY-B0258S1

Gemfibrozil-d6-1
Gemfibrozil-d6-1 (CI-719-d6-1) is the deuterium labeled Gemfibrozil (HY-B0258). Gemfibrozil is an activator of PPAR-α, used as a lipid-lowering agent; Gemfibrozil is also a nonselective inhibitor of several P450 isoforms, with K_i values for CYP2C9, 2C19, 2C8, and 1A2 of 5.8, 24, 69, and 82 μM, respectively .

HY-B1184S2

Mephenytoin-d8
Mephenytoin-d₈ is the deuterium labeled Mephenytoin[1]. Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate[2].

HY-B1184S3

Mephenytoin-13C,d3
Mephenytoin-13C,d3 is a deuterated labeled Mephenytoin . Mephenytoin, an anticonvulsant, is the CYP2C19 and CYP2B6 substrate .

HY-B2015S

Carbosulfan-d18
Carbosulfan-d₁₈ is the deuterium labeled Carbosulfan. Carbosulfan inhibited relatively potently CYP3A4 and moderately CYP1A1/2 and CYP2C19 in pooled HLM (human livers). Carbosulfan activation is predominantly catalyzed in humans by CYP3A4.

HY-B0113S

Omeprazole-d₃ 1 Publications Verification
Omeprazole-d₃ is deuterium labeled Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].

HY-103392S

Stiripentol-d9
Stiripentol-d₉ is the deuterium labeled Stiripentol. Stiripentol (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediatated by CYP3A4 (noncompetitively) and CYP2C19 (competitively) with Ki of 1.59±0.07 and 0.516±0.065 μM and IC50 of 1.58 and 3.29 μM, respectively[1][2].

HY-17356S

Fenofibrate-d6
Fenofibrate-d₆ is the deuterium labeled Fenofibrate. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively.

HY-17356S2

Fenofibrate-13C6
Fenofibrate-13C6 is a deuterated labeled Fenofibrate . Fenofibrate is a selective PPARα agonist with an EC₅₀ of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC₅₀s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for *CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4*, respectively.

HY-17356S1

Fenofibrate-d4
Fenofibrate-d₄ is the deuterium labeled Fenofibrate[1]. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively[2][3].

HY-N6948S

Linalyl acetate-d6

Linalyl acetate-d₆ is deuterated labeled Omeprazole (HY-B0113). Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0113S1

Omeprazole-d3-1

Omeprazole-d₃-1 is the deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-B0113S4

Omeprazole-d3 sodium

Omeprazole-d₃ sodium is deuterated labeled Omeprazole (HY-B0113). Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a K_i of 2 to 6 μM . Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria .Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor) .

HY-B0113S3

Omeprazole-13C,d3

Omeprazole- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM[1]. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria[2].Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[3].

HY-100386S

Ticlopidine-d4

Ticlopidine-d4 is the deuterium labeled Ticlopidine. Ticlopidine (PCR 5332), an antithrombotic proagent, acts as an allosteric, noncompetitive inhibitor of CD39 with the IC50 of 81.7 μM. Ticlopidine blocks several NTPDase isoenzymes with IC50s of 170 μM and 149 μM for NTPDase2 and NTPDase3, respectively[1]. Ticlopidine is an inhibitor of CYP2C19 human liver cytochrome. Ticlopidine inhibits CYP2C9 and CYP3A4 with IC50s of 26.0 and 32.3 μM, respectively[2][3].

HY-17459S

Clopidogrel-d3 hydrogen sulfate

Clopidogrel-d₃ (hydrogen sulfate) is the deuterium labeled Clopidogrel hydrogen sulfate[1]. Clopidogrel hydrogen sulfate is an antiplatelet agent to prevent blood clots. Clopidogrel hydrogen sulfate inhibits CYP2B6 and CYP2C19 with IC50s of 18.2 nM and 524 nM, respectively. Clopidogrel hydrogen sulfate is a potent antithrombotic agent that inhibits ADP-induced platelet aggregation．Clopidogrel hydrogen sulfate also is an orally active P2Y(12) inhibitor[2][3][4][5][6].

HY-131968

BMS-986202

BMS-986202 is a potent, selective and orally active Tyk2 inhibitor that binds to Tyk2 JH2 with an IC₅₀ value of 0.19 nM and a K_i of 0.02 nM. BMS-986202 is remarkably selective over other kinases including Jak family members. BMS-986202 is also a weak inhibitor of CYP2C19 with an IC₅₀ value of 14 μM. BMS-986202 can be used for IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus research. BMS-986202 is a de novo deuterium .

HY-163816

Antiproliferative agent-53-d3

Antiproliferative agent-53-d3 (Compound C1) is an inhibitor for theta-mediated end joining (TMEJ) in HEK293 cell with an IC₅₀ of 0.14 µM. Antiproliferative agent-53-d3 is the inhibitor for CYP2C19 and CYP2C9 with IC₅₀ of 0.77 and 3.1 µM. Antiproliferative agent-53-d3 inhibits the proliferation of DNA repair-compromised cells, with IC₅₀ of 8.1 µM for BRCA2 ^-/- DLD-1. Antiproliferative agent-53-d3 exhibits good pharmacokinetic characteristics in CD-1 mice .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

2C19

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products